Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study by Tomonori Makiguchi, Hisashi Tanaka, Kei Morikawa, Aya Hirata, Hidetoshi Itani, Shigeru Tanzawa, Kageaki Watanabe, Hiroyuki Yasuda, Kazuya Horiuchi, Hideyuki Nakagawa, Yoshitaka Seki, Yoshiro Nakahara, Kentaro Hayashi, Nobumasa Takahashi, Takeo Endo, Akihiro Bessho, Tetsuya Okano, Kiyoshi Takeyama, Akikazu Kawase, Makoto Endo, Toshiya Maekura, Kenji Nemoto, Nagio Takigawa, Kazuma Kishi, Kenzo Soejima, Yusuke Okuma, Akira Togashi, Noriyuki Matsutani, Hiroki Shinchi, Koji Ueda, Nobuhiko Seki

Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

Get full text